Neisvac-C

Tetanus toxoid, algeldrate, Neisseria meningitidis group C polysaccharide, the active ingredient in Neisvac‑C, is a vaccine presented as an injectable solution for intramuscular use. It induces active immunity that protects individuals against tetanus toxin and Neisseria meningitidis group C bacterial infection.

GNH USA supplies Neisvac‑C as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance, regulatory compliance, and reliable cold‑chain logistics for global distribution.

Neisvac‑C is a combination vaccine that targets bacterial toxin and capsular polysaccharide antigens, providing preventive immunity against tetanus and meningococcal group C infections in at‑risk populations. - Tetanus: Induces protective antibodies that neutralize tetanus toxin, preventing tetanus disease. - Neisseria meningitidis group C infection: Generates immunity against the group C capsular polysaccharide, reducing the risk of meningococcal disease. - Booster immunization: Reinforces immunity in individuals previously vaccinated against tetanus and meningococcal group C.

Neisvac‑C, like other injectable vaccines, may be associated with local and systemic reactions.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: transient erythema or edema around the injection area. - Fever: low‑grade temperature rise within 24‑48 hours.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurologic disorder reported after vaccination. - Seizures: uncommon febrile seizures in susceptible individuals.

Before administering Neisvac‑C, healthcare professionals should observe several precautions to ensure safety and vaccine effectiveness. - Allergy screening: Avoid use in individuals with known hypersensitivity to any vaccine component. - Acute illness: Defer vaccination in persons with moderate or severe febrile illness until recovery. - Pregnancy: Use only when the benefit outweighs potential risk; consult a physician. - Immunocompromised patients: Antibody response may be reduced; monitor protective titres. - Concomitant immunoglobulin: Postpone vaccine at least two weeks after receiving blood products to prevent interference. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Neisvac‑C may interact with certain biologic products or medications that affect the immune system.

Major Interactions (Avoid): - Immunoglobulin or blood products: Can neutralize vaccine antigens and diminish immune response if given within two weeks. - Live bacterial vaccines: Concurrent administration may compromise efficacy; schedule separately.

Moderate Interactions (Monitor Closely): - Immunosuppressive therapy: May reduce antibody production; assess serologic response. - Antipyretic agents: May mask fever, a sign of reaction; monitor patient symptoms. - Other vaccines: Simultaneous administration is generally safe but may increase local reactogenicity; observe for heightened side effects.